Perrigo Company has transferred a portfolio of preclinical research assets, which it acquired through its December 2013 acquisition of Elan Corporation plc, to drug discovery and development company, Imago Pharmaceuticals.
Acknowledging strong public skepticism in Europe over free trade talks with the U.S., the...
Daiichi Sankyo Company and Ambit Biosciences, jointly announced today that they have entered...
More than a dozen U.S. senators from both parties are calling on the Obama administration to broaden a Medicaid program for the nation's frailest seniors, calling it a proven alternative to pricier nursing home care as states seek to limit long-term medical costs.
The U.N. mission to combat Ebola opened its headquarters on Monday in Ghana, where it will coordinate aid for the accelerating West African crisis.The spread of Ebola has spiraled into the worst ever outbreak, and the World Health Organization says it is has linked more than 3,000 deaths to the disease, although that is likely an underestimate of the true toll.
A jury is now deliberating the sentence of a Texas cancer researcher convicted of poisoning her colleague and lover by spiking his coffee with a chemical found in antifreeze. Jurors got the case Monday after closing arguments in the punishment phase of the trial of Dr. Ana Maria Gonzalez-Angulo, a breast cancer doctor based at Houston's famed Texas Medical Center.
FDA Approves NeuroGenetic Pharmaceuticals Application to Begin Clinical Trials for Its Alzheimer’s Disease CompoundSeptember 29, 2014 12:06 pm | Comments
The U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application from NeuroGenetic Pharmaceuticals, Inc. (NGP) to begin clinical trials on its NGP 555 compound to treat and prevent Alzheimer’s disease (AD).
A potential drug to combat a complication of severe infections known as a cytokine storm will advance in development under an agreement announced today by the U.S. Department of Health and Human Services. A cytokine storm can complicate recovery and in extreme cases can drive the body’s organs to shut down, causing death.
Five babies tested have positive for tuberculosis in West Texas after a nurse assistant at an El Paso hospital nursery exposed hundreds of infants to the disease between September 2013 and last month.
The Centers for Disease Control and Prevention on Friday sent doctors an alert about the polio-like cases and said the germ — enterovirus 68 — was detected in four out of eight of the sick children who had a certain medical test. The status of the ninth case is unclear.
Teen girls who have sex should use IUDs or hormonal implants — long-acting birth control methods that are effective, safe and easy to use, the nation's most influential pediatricians' group recommends.
An American doctor who was exposed to the Ebola virus while volunteering in Sierra Leone was admitted Sunday to a hospital at the National Institutes of Health near the nation's capital.
The Nebraska hospital that treated an American aid worker infected with Ebola has fired two workers accused of violating the man's privacy by looking at his medical file.
Allergan announced today that the U.S. Food and Drug Administration (FDA) has approved OZURDEX® (dexamethasone intravitreal implant) 0.7 mg, a sustained-release biodegradable steroid implant, for the treatment of diabetic macular edema (DME).
The Waltham, Massachusetts, company said Monday it will spend $600 million in cash and another $75 million in stock on the privately held Lumara, which makes Makena, a treatment designed to reduce the risk of premature birth.
Shares of Exelixis jumped Monday before markets opened and after the drugmaker said its treatment for a deadly form of skin cancer fared better than another drug in a late-stage clinical study.
Alimera Sciences and pSivida said Friday the FDA approved their eye disease implant Iluvien. Iluvien is an implant delivered by injection that is intended to treat diabetic macular edema, a condition that can cause blurred vision and blindness.
Pfizer announced that it has completed its acquisition of pharmaceutical development company, InnoPharma, Inc., and Abbott has acquired control of CFR Pharmaceuticals, more than doubling its Latin American-branded generics pharmaceutical presence.